拉米夫定联合治疗失代偿期肝硬化的临床讨论  

Lamivudine combination therapy in the treatment of decompensated cirrhosis of the clinical discussion

作　　者：刘本付[1] 

机构地区：[1]含山县人民医院感染科,安徽含山238100

出　　处：《世界最新医学信息文摘》2013年第31期8-9,共2页World Latest Medicine Information Electronic Version

摘　　要：目的：探讨阿德福韦酯联合拉米夫定治疗失代偿期乙型肝炎肝硬化的临床疗效。方法61例失代偿期肝硬化患者在一般治疗基础上，随机分为治疗组31例，给予阿德福韦酯10mg/d 联合拉米夫定100mg/d 口服；对照组30例，给予阿德福韦酯10mg/d 口服，治疗12个月。治疗前后都观察血清总胆红素、血清 HBV DNA 水平以及变化。结果阿德福韦酯联合拉米夫定治疗组与对照组 HBV DNA 阴转率分别为87.09%、60.0%，治疗组明显优于对照组；肝功能 Child-Pugh 评分分别为（6.8±1.4）分、（7.5±1.6）分，治疗组明显优于对照组（P 〈0.05）。结论阿德福韦酯联合拉米夫定治疗失代偿期乙型肝炎肝硬化优于单独使用阿德福韦酯治疗，且不易产生耐药性，患者能长期稳定病情。Objective To investigate the clinical efficacy of adefovir dipivoxil and lamivudine therapy in patients with decompensated liver cirrhosis resulting from hepatitis B. Methods 61 patients with decompensated liver cirrhosis in general therapy were included and 31 patients with adefovir 10 mg and lamivudine 100 mg once daily,30 with adefovir 10 mg once daily for 12 months. HBV dna and liver function were observed before and after treatmert. Results the negative-transformed rate of HBV DNA in combined group and adefovir dipivoxil were 87.09% and 60%,respectively;and the Child-Pugh scores were （6.8±1.4）scores, （7.5±1.6）scores, respectively.Conclusions combination of adefovir dipivoxil and lamivudine in treatment of decompensated liver cirrhosis resulting from hepatitis B has an advantage over adefovir dipivoxil treatment alone. adefovir dipivoxil combined with lamivudine treatment of hepatitis B cirrhosis shows no resistance and patients of could receive a long-term drugs with stable condition.

关 键 词：肝硬化 阿德福韦酯 拉米夫定 

分 类 号：R657.31[医药卫生—外科学]